Leslie A. Bucheit

Featured in: Favicon

Articles

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers - Communications Medicine

Dec 2, 2024 | nature.com | Pingfu Fu |Rani Bansal |Leslie A. Bucheit

AbstractBreast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, including in these “cold tumors”.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.